Daniele S.O. Daian e Silva

Daniele S.O. Daian e Silva

Auto-generated profile, based on publicly available information

Daniele S.O. Daian e Silva

Laboratório de Virologia Básica e Aplicada, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Immunology Letters
Verified
Journal Article
Closed access
APAdriana Alves Oliveira Paim
Adriana Alves Oliveira Paim
ÁLÁgata Lopes-Ribeiro
Ágata Lopes-Ribeiro
DSDaniele S.O. Daian e Silva
Daniele S.O. Daian e Silva
LALuis Adan F. Andrade
Luis Adan F. Andrade
TMThais F.S. Moraes
Thais F.S. Moraes
JCJordana Grazziela Alves Coelho-dos-Reis
Jordana Grazziela Alves Coelho-dos-Reis

19 December 2023 in Virology Journal
Verified
Journal Article
Open access
PDF file
DSD. S. O. Daian e Silva
D. S. O. Daian e Silva
LCLaura Jorge Cox
Laura Jorge Cox
ARA. S. Rocha
A. S. Rocha
ÁLÁ. Lopes-Ribeiro
Á. Lopes-Ribeiro
JSJ. P. C. Souza
J. P. C. Souza
EBEdel F. Barbosa-Stancioli
Edel F. Barbosa-Stancioli
Human T-lymphotropic virus 1 (HTLV-1) is associated with the development of several pathologies and chronic infection in humans. The inefficiency of the available treatments and the challenge in developing a protective vaccine highlight the need to produce effective immunotherapeutic tools. The HTLV-1 basic leucine zipper (bZIP) factor (HBZ) plays an important role in the HTLV-1 persistence, conferring a survival advantage to infected cells by reducing the HTLV-1 proteins expression, allowing infected cells to evade immune surveillance, and enhancing cell proliferation leading to increased proviral load. We have generated a recombinant Modified Virus Vaccinia Ankara (MVA-HBZ) and a plasmid DNA (pcDNA3.1(+)-HBZ) expressing a multiepitope protein based on peptides of HBZ to study the immunogenic potential of this viral-derived protein in BALB/c mice model. Mice were immunized in a prime-boost heterologous protocol and their splenocytes (T CD4+ and T CD8+) were immunophenotyped by flow cytometry and the humoral response was evaluated by ELISA using HBZ protein produced in prokaryotic vector as antigen. T CD4+ and T CD8+ lymphocytes cells stimulated by HBZ-peptides (HBZ42–50 and HBZ157–176) showed polyfunctional double positive responses for TNF-α/IFN-γ, and TNF-α/IL-2. Moreover, T CD8+ cells presented a tendency in the activation of effector memory cells producing granzyme B (CD44+High/CD62L−Low), and the activation of Cytotoxic T Lymphocytes (CTLs) and cytotoxic responses in immunized mice were inferred through the production of granzyme B by effector memory T cells and the expression of CD107a by CD8+ T cells. The overall data is consistent with a directive and effector recall response, which may be able to operate actively in the elimination of HTLV-1-infected cells and, consequently, in the reduction of the proviral load. Sera from immunized mice, differently from those of control animals, showed IgG-anti-HBZ production by ELISA. Our results highlight the potential of the HBZ multiepitope protein expressed from plasmid DNA and a poxviral vector as candidates for therapeutic vaccine.

6 March 2020 in Brazilian Journal of Microbiology
Verified
Journal Article
Open access
PDF file
DSDanielle Soares de Oliveira Daian e Silva
Danielle Soares de Oliveira Daian e Silva
EBEdel F. Barbosa-Stancioli
Edel F. Barbosa-Stancioli
JCJordana Graziela Alves Coelho-Dos-Reis
Jordana Graziela Alves Coelho-Dos-Reis
Flavio FonsecaFlavio Fonseca
Flavio Fonseca
Porcine circovirus 2 (PCV2) infections are related to a number of syndromes and clinical manifestations, generally known as Porcine circovirus-associated diseases, which are related to losses in the swine industry. There are commercially available vaccines and new vaccines being tested, however, persistency of the PCV2 as an important pig pathogen, and the growing number of affected farms in different countries have suggested that there is room for vaccine improvement. In this study, we describe the construction and testing of a recombinant live vaccine based on a modified Vaccinia virus Ankara (MVA) vector expressing the PCV2b capsid protein (CAP). Using a two-dose homologous vaccination regimen, in mice, we demonstrated that the vaccine induced high titers of anti-PCV2 antibodies. The vaccine is stable upon lyophilization, and, together with the good immunogenicity potential observed, the results support further evaluation of the MVA-CAP vaccine in the target species.

25 April 2023 in Veterinary Vaccine
Verified
Journal Article
Open access
DSD.S.O. Daian e Silva
D.S.O. Daian e Silva
TPT.M.G. Pinho
T.M.G. Pinho
RRR.P. Rocha
R.P. Rocha
SOS.B. Oliveira
S.B. Oliveira
GFG.M. Franco
G.M. Franco
Flavio FonsecaFlavio Fonseca
Flavio Fonseca